August 25, 2022
Life Sciences
  • A large Israeli study found that Pfizer Inc.’s COVID-19 treatment Paxlovid lowered hospitalization rates in 65-year-olds and older by about 75 percent. However, people ages 40-64 who took the drug shortly after infection saw little to no benefit. The study was conducted via compiled data from a large health system in Israel rather than through a randomized study that enrolled patients and had a control group. (Article here)